Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1992 Sep;51(9):1036–1038. doi: 10.1136/ard.51.9.1036

Decreased level of antibodies against Helicobacter pylori in patients with rheumatoid arthritis receiving intramuscular gold.

M Janssen 1, B A Dijkmans 1, J P Vandenbroucke 1, W van Duijn 1, A S Peña 1, C B Lamers 1
PMCID: PMC1004832  PMID: 1417132

Abstract

BACKGROUND: Sodium aurothiomalate has been reported to have in vitro activity against Helicobacter pylori. Intramuscular gold, as given to patients with rheumatoid arthritis (RA), may therefore influence the colonisation of the gastric mucosa with H pylori. METHODS: Two groups were compared. One group of 42 patients was treated with intramuscular gold; the other group of 58 patients was treated with antimalarial drugs. Antibodies to H pylori (IgA and IgG) were assessed by an enzyme linked immunosorbent assay (ELISA) and total IgA and IgG were measured by nephelometry. RESULTS: IgA and IgG antibody titres against H pylori and total IgA and IgG levels were lower in the patients treated with gold than in the group treated with antimalarial drugs. The ratio of IgA antibodies to H pylori to total IgA antibodies and the ratio of IgG antibodies to H pylori to total IgG antibodies were lower in the group treated with gold. The percentage of seropositivity to H pylori was significantly lower in the group treated with gold than in the group treated with antimalarial drugs for the two IgA antibodies (35 and 55% respectively) and IgG antibodies to H pylori (40 and 65% respectively). CONCLUSIONS: Although this study cannot completely exclude the possibility that a suppressive effect of intramuscular gold on total immunoglobulin production plays a part in the decrease in the titres of IgA antibodies to H pylori and IgG antibodies to H pylori, the lower ratios of antibodies to H pylori to total immunoglobulin antibodies and the lower percentages of seropositivity to H pylori in the group treated with gold suggests that treatment with intramuscular gold decreases H pylori colonisation.

Full text

PDF
1037

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blaser M. J. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis. 1990 Apr;161(4):626–633. doi: 10.1093/infdis/161.4.626. [DOI] [PubMed] [Google Scholar]
  2. Deaton C. D., Maxwell K. W., Smith R. S., Creveling R. L. Use of laser nephelometry in the measurement of serum proteins. Clin Chem. 1976 Sep;22(9):1465–1471. [PubMed] [Google Scholar]
  3. Feldman M. Helicobacter pylori and the etiology of duodenal ulcer: necessary but not sufficient. Am J Med. 1991 Dec;91(6):563–565. doi: 10.1016/0002-9343(91)90206-d. [DOI] [PubMed] [Google Scholar]
  4. Gottlieb N. L., Smith P. M., Smith E. M. Tissue gold concentration in a rheumatoid arthritic receiving chrysotherapy. Arthritis Rheum. 1972 Jan-Feb;15(1):16–22. doi: 10.1002/art.1780150103. [DOI] [PubMed] [Google Scholar]
  5. Hanly J. G., Hassan J., Whelan A., Feighery C., Bresnihan B. Effects of gold therapy on the synthesis and quantity of serum and synovial fluid IgM, IgG, and IgA rheumatoid factors in rheumatoid arthritis patients. Arthritis Rheum. 1986 Apr;29(4):480–487. doi: 10.1002/art.1780290404. [DOI] [PubMed] [Google Scholar]
  6. Keers R. Y. The gold rush 1925-35. Thorax. 1980 Dec;35(12):884–889. doi: 10.1136/thx.35.12.884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kurata J. H. What in the world is happening to ulcers? Gastroenterology. 1983 Jun;84(6):1623–1625. [PubMed] [Google Scholar]
  8. Langman M. J. Epidemiologic evidence on the association between peptic ulceration and antiinflammatory drug use. Gastroenterology. 1989 Feb;96(2 Pt 2 Suppl):640–646. doi: 10.1016/s0016-5085(89)80060-5. [DOI] [PubMed] [Google Scholar]
  9. Laporte J. R., Carné X., Vidal X., Moreno V., Juan J. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding. Lancet. 1991 Jan 12;337(8733):85–89. doi: 10.1016/0140-6736(91)90744-a. [DOI] [PubMed] [Google Scholar]
  10. Lorber A., Simon T., Leeb J., Peter A., Wilcox S. Chrysotherapy. Suppression of immunoglobulin synthesis. Arthritis Rheum. 1978 Sep-Oct;21(7):785–791. doi: 10.1002/art.1780210708. [DOI] [PubMed] [Google Scholar]
  11. Perez-Perez G. I., Dworkin B. M., Chodos J. E., Blaser M. J. Campylobacter pylori antibodies in humans. Ann Intern Med. 1988 Jul 1;109(1):11–17. doi: 10.7326/0003-4819-109-1-11. [DOI] [PubMed] [Google Scholar]
  12. Peterson W. L. Helicobacter pylori and peptic ulcer disease. N Engl J Med. 1991 Apr 11;324(15):1043–1048. doi: 10.1056/NEJM199104113241507. [DOI] [PubMed] [Google Scholar]
  13. Peña A. S., Endtz H. P., Offerhaus G. J., Hoogenboom-Verdegaal A., van Duijn W., de Vargas N., den Hartog G., Kreuning J., van der Reyden J., Mouton R. P. Value of serology (ELISA and immunoblotting) for the diagnosis of Campylobacter pylori infection. Digestion. 1989;44(3):131–141. doi: 10.1159/000199902. [DOI] [PubMed] [Google Scholar]
  14. Rauws E. A., Langenberg W., Houthoff H. J., Zanen H. C., Tytgat G. N. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology. 1988 Jan;94(1):33–40. [PubMed] [Google Scholar]
  15. Roth S. H., Bennett R. E. Nonsteroidal anti-inflammatory drug gastropathy. Recognition and response. Arch Intern Med. 1987 Dec;147(12):2093–2100. [PubMed] [Google Scholar]
  16. Schoen R. T., Vender R. J. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med. 1989 Apr;86(4):449–458. doi: 10.1016/0002-9343(89)90344-6. [DOI] [PubMed] [Google Scholar]
  17. Shallcross T. M., Rathbone B. J., Wyatt J. I., Heatley R. V. Helicobacter pylori associated chronic gastritis and peptic ulceration in patients taking non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 1990 Oct;4(5):515–522. doi: 10.1111/j.1365-2036.1990.tb00498.x. [DOI] [PubMed] [Google Scholar]
  18. Singh G., Fries J. F., Williams C. A., Zatarain E., Spitz P., Bloch D. A. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol. 1991 Feb;18(2):188–194. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES